Harvoni vs Mavyret
Side-by-side cost comparison based on Medicare Part D data
Harvoni
Ledipasvir/Sofosbuvir
Manufactured by Gilead
Mavyret
Glecaprevir/Pibrentasvir
Manufactured by AbbVie
Harvoni costs 5% less per claim than Mavyret ($24,958.00 vs $26,250.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Harvoni | Mavyret |
|---|---|---|
| Avg Cost Per Claim | $24,958.00 | $26,250.00 |
| Total Medicare Spending | $1.2B | $945.0M |
| Total Beneficiaries | 12,000 | 9,000 |
| Total Claims | 48,000 | 36,000 |
| Annual Cost/Patient | $99,833.00 | $105,000.00 |
| Year-over-Year Change | -38.2% | -21.4% |
| Generic Available | No | Yes |
| Patent Expiration | Oct 10, 2030 | Jan 31, 2023 |
| Manufacturer | Gilead | AbbVie |
| Condition | Hepatitis C | Hepatitis C |
| Generic Name | Ledipasvir/Sofosbuvir | Glecaprevir/Pibrentasvir |
Harvoni vs Mavyret: What the Data Shows
Harvoni (Ledipasvir/Sofosbuvir) and Mavyret (Glecaprevir/Pibrentasvir) are both used to treat hepatitis c. Based on Medicare Part D data, Harvoni costs $24,958.00 per claim, which is 5% less than Mavyret at $26,250.00 per claim.
Medicare spent $1.2B on Harvoni and $945.0M on Mavyret. In terms of patient reach, Harvoni serves more beneficiaries (12,000 vs 9,000).
Year-over-year spending changed -38.2% for Harvoni and -21.4% for Mavyret.
Mavyret has a generic available, while Harvoni remains brand-only until its patent expires Oct 10, 2030.
Frequently Asked Questions
Harvoni is cheaper at $24,958.00 per claim, compared to $26,250.00 for Mavyret. That makes Harvoni about 5% less expensive per claim based on Medicare Part D data.
Yes, both Harvoni and Mavyret are used to treat hepatitis c. Your doctor can help determine which medication is more appropriate for your specific situation.
Mavyret has a generic version (Glecaprevir/Pibrentasvir) available, which is typically much cheaper. Harvoni is currently brand-only, with patent expiring Oct 10, 2030.
Medicare Part D spent $1.2B on Harvoni covering 12,000 beneficiaries, and $945.0M on Mavyret covering 9,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.